Continuous Delivery of Levodopa in Patients With Advanced Idiopathic Parkinsons Disease - Cost-benefit

University Hospital, Akershus10 enrolled

Overview

An open, observational health economic study to estimate marginal cost and health consequences of replacing conventional Parkinsons disease therapy with intraduodenal levodopa administered continuously

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Parkinson Disease

Interventions

Levodopa (drug), intraduodenal administrationDRUG

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Clinical diagnosis of of idiopathic Parkinsons disease * Motor fluctuations despite optimised per oral treatment Exclusion Criteria: * Severe dementia, confusion, psychosis or depression * Patients with contraindications against levodopa treatment

Locations (2)

Akershus University Hospital

Nordbyhagen, Norway

Dept Neurology, Ulleval University Hospital

Oslo, Norway

Outcomes

Primary Outcomes

Marginal cost per QALY of replacing conventional treatment with intraduodenal levodopa

Time frame: one year

Quality of life at three, six, nine and twelve months(Assessed by Nottingham Health Profile (NHP), Parkinson Disease Questionnaire (PDQ39), 15D Quality of life)

Secondary Outcomes

Parkinson related function at three, six, nine and twelve months(UPDRS, Hoehn and Yahr scores, Schwab and England)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.